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Even in the 21st century, tuberculosis continues to be a problem. Although the number of cases continues gradually to
decrease in the United States, cases get more difficult to treat, specifically those that are multiple-drug resistant. Infection
of one-third of the world’s population ensures that tuberculosis will not disappear in the near future. In light of this, it will
be useful to know the goals for the health care system and how these goals may be accomplished. Laboratory testing in the
mycobacteriology field is experiencing more changes today than ever before. Determining what assays will be most useful
to the clinician is a challenge, and acceptance of the new technology by the medical community an even greater one. Clinicians
must use the best available resources to determine the most appropriate care for their patients and work together with the
laboratory to ensure that the communication channels are open. This review focuses on current state-of-the-art resources
useful for accurate and rapid laboratory diagnosis of mycobacterial infections.
Despite the progress in promoting the public’s health and en-
suring quality care, communities in the United States have been
surprised by the resurgence of an old disease with a new twist:
drug-resistant tuberculosis. How could this happen? As the
incidence of tuberculosis declined in the 1960s and early 1970s,
so did programs to control it [1]. Beginning in 1980, the seeds
for an impending disaster were sown. Federal funding targeted
specifically for tuberculosis control was phased out and replaced
with general public health block grants to the states. Many states
and cities decided to spend less money to fight tuberculosis. It
has been 115 years since the Centers for Disease Control and
Prevention (CDC) first observed a deviation from the expected
decline in tuberculosis [2]. Although the resurgence of tuber-
culosis in inner cities has been largely attributed to the HIV
epidemic, Brudney and Dobkin [3] clearly showed that wors-
ening economic and social conditions, including an increase in
homelessness, have contributed substantially to an increase in
tuberculosis. Since 1993, the incidence of tuberculosis has been
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declining again. However, the cost to contain the resurgence
of tuberculosis has been phenomenal. In New York City, for
example, there were 120,000 excess cases of the disease from
1979 through 1994 that would not have occurred if previous
downward trends had continued. The resulting costs were es-
timated to easily exceed $1 billion [1]. The challenge in the
years to come will be to increase the political will to fight
tuberculosis, and thus eliminate it not only in New York City
but in the entire United States and beyond.
The emergence of strains of Mycobacterium tuberculosis that
are resistant to antituberculosis agents, although not a novel
phenomenon, has recently received increased attention, largely
because of the dramatic outbreaks of multidrug-resistant tu-
berculosis in HIV-infected patients in New York and Florida
[4]. Delayed diagnoses, inadequate treatment regimens, high
mortality, and significant rates of nosocomial transmission have
characterized these outbreaks [5].
Overall, the World Health Organization estimated that there
were 18 million cases of tuberculosis in 1998, 80% concentrated
in 22 high-burden countries, led by India and China [6]. Drug-
resistant tuberculosis became a worldwide problem in both
immunocompetent and HIV-infected populations [7, 8]. Al-
though progress is noticeable, control of tuberculosis is ham-
pered by the fact that tuberculosis and HIV disease are closely
linked in a mutually disadvantageous synergy: HIV infection
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Table 1. Newly discovered nontuberculous mycobacterial species described since
1990.
Year described
Mycobacterium
species
Reference
(first description)
Rate of
growth
Isolated from
clinical specimens
1990 M. cookii [10] Slow No
1992 M. abscessus [11] Rapid Yes
1992 M. alvei [12] Rapid Yes
1992 M. confluentis [13] Rapid Yes
1992 M. peregrinum [11] Rapid Yes
1993 M. brumae [14] Rapid Yes
1993 M. celatum [15] Slow Yes
1993 M. genavense [16] Slow Yes
1993 M. hiberniae [17] Slow No
1993 M. intermedium [18] Slow Yes
1993 M. interjectum [19] Slow Yes
1994 M. chlorophenolicum [20] Rapid No
1995 M. branderi [21] Slow Yes
1995 M. conspicuum [22] Slow Yes
1995 M. mucogenicum [23] Rapid Yes
1996 M. hodleri [24] Rapid No
1996 M. lentiflavum [25] Slow Yes
1996 M. triplex [26] Slow Yes
1997 M. hassiacum [27] Rapid Yes
1997 M. heidelbergense [28] Slow Yes
1997 M. mageritense [29] Rapid Yes
1997 M. novocastrense [30] Rapid Yes
1998 M. bohemicum [31] Slow Yes
1999 M. goodii [32] Rapid Yes
1999 M. murale [33] Rapid No
1999 M. tusciae [34] Slow Yes
1999 M. wolinskyi [32] Rapid Yes
2000 M. botniense [35] Slow No
2000 M. septicum [36] Rapid Yes
2000 M. kubicae [37] Slow Yes
2000 M. elephantis [38] Rapid No
2000 M. heckeshornense [39] Slow Yes
promotes the progression of M. tuberculosis infection to disease,
and tuberculosis accelerates the course of HIV disease [9].
In 1975, the genus Mycobacterium comprised some 30 spe-
cies; 25 years later, it comprises close to 100. The newly dis-
covered nontuberculous mycobacterial species described since
1990 and their origin, whether from clinical specimens or else-
where, are listed in table 1. This plethora of species poses an
additional challenge for the clinical mycobacteriology labora-
tory to provide timely services. Furthermore, some of the more
recently described species (e.g., Mycobacterium haemophilum,
Mycobacterium genavense) require special growth conditions,
necessitating an exquisite collaboration between the clinician
requesting the test and the laboratory professional performing
the test.
M. tuberculosis, Mycobacterium bovis, and other entities
within this taxon (M. bovis bacille Calmette-Gue´rin [BCG],
Mycobacterium africanum, Mycobacterium microti, and Myco-
bacterium canettii) are referred to as the M. tuberculosis com-
plex, and many clinical microbiology laboratories identify these
organisms only to the level of the complex. This practice is
supported by commercial kits, such as the AccuProbe assay
(Gen-Probe); nucleic acid amplification–based (NAA) tech-
niques; and the radiometric NAP (p-nitro-a-acetylamino-b-
hydroxypropiophenone) assay, none of which can differentiate
between members of the M. tuberculosis complex. Such incom-
plete identification can hamper patient management, in the
case of BCG dissemination as a complication of BCG immu-
nostimulation against bladder cancer [40], and can undermine
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Table 2. Services offered by the Florida Department of Health’s FAST TRACK Program.
Service Times available Comments
Staffing Daily —
Microscopy Daily 24-h turnaround time from receipt of specimen to
availability of AFB smear results, which are per-
formed with use of fluorochrome staining and
confirmed with use of carbol fuchsin staining;
first-time positive results are reported to the
health care provider by telephone
Nucleic acid amplification Monday–Saturday Used to determine rapidly (in 1 day) whether a
smear-positive sputum sample contains Myco-
bacterium tuberculosis complex; available for
smear-negative specimens only on request
Detection of growth in
culture
Daily Up to 6 weeks time to detection with use of BAC-
TEC 12B liquid medium, Lo¨wenstein-Jensen
slants (glass test tubes; egg-based medium),
7H10 or selective 7H11 biplates (agar-based me-
dium); report issued as soon as growth of myco-
bacteria has been detected
PCR restriction enzyme
analysis
Daily Primary means to rapidly identify and confirm M.
tuberculosis complex or nontuberculous myco-
bacteria in culture
DNA probes Daily Used to rapidly identify and confirm M. tuberculo-
sis complex or M. avium complex in culture
HPLC Weekly Used to identify nontuberculous mycobacteria
Susceptibility testing Daily Determines BACTEC 12B liquid–media susceptibili-
ties for first-line and second-line antituberculosis
drugs; drug resistance confirmed by proportion
method
DNA typing On request Performed only for M. tuberculosis complex strains
NOTE. AFB, acid-fast bacilli.
important public health investigations, in the case of possible
cattle-to-human transmission of M. bovis [41]. In addition, M.
microti [42], M. africanum, and M. canettii [43] should be
recognized at the species level to enable collection of more
information about their epidemiology.
Thus, the mycobacteriology laboratory plays an important
role in primary care and public health by providing more ac-
curate results and having a shorter turnaround time than do
less-specialized clinical laboratories. The laboratory diagnosis
of mycobacterial infections, tuberculosis in particular, must be
expedited to improve better patient management and to save
limited resources within the health care system. In 1986, the
British Medical Research Council published data about the in-
fluence of initial drug resistance on the response of patients
with pulmonary tuberculosis to short-course chemotherapy
[44]. In contrast to the high success rate of short-course regi-
mens in cases with initial resistance to isoniazid and strepto-
mycin, the response of the few cases with initial resistance to
rifampin was poor. Therefore, it is imperative to recognize ri-
fampin resistance as early as possible, to allow for adequate
adjustment of the drug-treatment regimen. The 2 most urgent
questions in a suspected case of tuberculosis, which need to be
rapidly addressed by the mycobacteriology laboratory, are
whether there are tubercle bacilli involved and, if so, whether
they are resistant to rifampin. A model for quick and accurate
laboratory services is that offered by the FAST TRACK program
in Florida, whose services are summarized in table 2.
The mycobacteriology laboratory has passed through several
phases in its effort to answer these questions accurately and
more rapidly: from using radiometric growth detection, in-
cluding susceptibility testing, in the mid-1980s, to using nu-
cleic-acid probes in the late 1980s, NAA in the mid-1990s, and
now DNA sequencing, which is available in a kit format. This
review updates recent developments in laboratory diagnostics
and provides ideas about how clinicians can assess and access
laboratory services. In addition, the review details the respon-
sibilities carried out by public health bodies and professional
societies to ensure access to newer technologies and described
realistic goals that may help to drive the future of mycobac-
teriology laboratory testing.
THE CLINICIAN-LABORATORY RELATIONSHIP
In recent years, there has been a growing body of new and
exciting methods in mycobacteriology, but there is not yet any
single test for tuberculosis that can stand alone [45]. Most
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important, complementary techniques should be used to gen-
erate complete and rapid information. The laboratory director
needs to decide which tests will be best performed in-house
and which specimens should be sent to a reference laboratory,
on the basis of the community to be served and the resources
available and in consultation with the infectious disease spe-
cialists, pneumologists, an/or other physicians involved. When
this partnership is established, the physicians will share the
responsibility for the quality and the timeliness of the laboratory
results.
In addition, laboratory test results should always be corre-
lated with the patient’s clinical presentation, and the clinician
should notify the laboratory when results are not consistent.
An established and ongoing professional relationship between
clinicians and the laboratory enables the recognition of inac-
curate results earlier and, therefore, may minimize the potential
harm to the patient. Previous reports [46, 47] have demonstrated
that ∼3%–4% of cultures for tuberculosis have false-positive re-
sults. In a study that analyzed drug-resistant tuberculosis [48],
13% of cultures had erroneous results; furthermore, in a study
of specimens from patients with negative results of smears for
acid-fast bacilli (AFB) and only 1 positive culture result [49],
erroneous results were reported for 56% of cultures. However,
it is possible that the error may have occurred in the pre-testing
phase, such as by use of a nonsterile bronchoscope for specimen
collection [50] or by detection of residual amplifiable M. tu-
berculosis DNA that could have remained in the sterile bron-
choscope [51]. These reports underscore the facts that laboratory
results alone (i.e., positive culture result or drug resistance) are
not enough to dictate a particular strategy for the patient’s care
and that a careful clinical correlation is necessary to make the
correct diagnosis. Health care providers and laboratory staff
need to communicate and cooperate to bridge any gap between
them. Only when clinicians and laboratories work together can
clinical outcomes be optimized.
QUALITY TESTING REQUIRES A QUALITY
SPECIMEN
Accurate, rapid microbiological diagnosis of tuberculosis and
other mycobacterial infections begins with proper specimen
collection and rapid transport of the specimen to the laboratory.
To ensure collection of the best possible specimen, the health
care worker has to be properly trained, and the patient has to
be provided with clearly presented instructions that they fully
understand. The clearly labeled specimen must be transported
to the laboratory quickly, because results of some tests, such
as AFB smears and NAA procedures, can reliably be reported
within 24–48 h of receipt in the laboratory.
To provide the best results, the volume of a sputum specimen
should exceed 5 mL [52]. In addition, other specimens may
be collected, such as urine, CSF, pleural fluid, bronchial-wash
samples, blood (reserved for immunocompromised patients,
especially patients with AIDS), material from abscesses, en-
dometrial scrapings, bone marrow, and other biopsy specimens
[53, 54]. Aerosol-producing procedures should be done in a
way that ensures the safety of the health care worker during
collection [55].
Most specimens will contain microorganisms other than my-
cobacteria. Therefore, the specimen has to be refrigerated if a
delay should occur, because otherwise overgrowth of the more
rapidly growing contaminants may occur. Unfortunately, very
often the laboratory is at the end of the decision tree for the
patient’s health improvement, especially in situations in which
the patient waits weeks until seeing a physician, the mycobac-
terial disease is not initially recognized, or the specimen sub-
mitted to the laboratory is substandard. The importance of
providing a high-quality and timely specimen should be con-
veyed to the health care provider. Health care providers and
laboratorians must communicate to ensure the best laboratory
testing.
REGULATIONS FOR PACKAGING AND
SHIPPING LABORATORY SPECIMENS
Laboratories must maintain the integrity of patient specimens
before the specimens are analyzed. Maintaining specimen in-
tegrity in the laboratory is not simple, and it becomes even
more complex when specimens are transported by public con-
veyance. Specimens must be kept from leaking and from being
crushed in unexpected accidents. They must be packed to pro-
tect both the specimens and those who handle them [56].
The regulations that apply depend on how the specimen is
sent. Each mode of transportation has its own rules. For spec-
imens sent by mail, the US Postal Service regulations regarding
dangerous goods should be followed. For specimens sent by
ground courier, Department of Transportation regulations
should be followed: regulations governing specimen transport
are incorporated in a document referred to as “49 CFR” [57].
If specimens are sent by air, the dangerous goods regulations
of the International Air Transportation Association and Inter-
national Civil Aviation Organization must be followed.
SAFETY
Safety in the mycobacteriology laboratory is of paramount con-
cern. Sputum samples and other clinical specimens from pa-
tients with known or suspected tuberculosis must be considered
potentially infectious. Aerosols must be controlled by the use
of biological safety cabinets and centrifuges with safety carriers,
and the laboratory staff must follow safety guidelines. All work
involving specimens or cultures must be performed in a bio-
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logical safety cabinet. This includes making smears, inoculating
media, adding reagents, opening centrifuge cups, sonication,
and any other potentially aerosol-producing procedures. The
use of respirators may be warranted for work in a biosafety
level 3 (BSL-3) laboratory and in a laboratory that grows large
amounts of M. tuberculosis, works with drug-resistant isolates,
or performs tasks with unknown risks. BSL-3 practices require
restricted laboratory access, directional air-flow with negative
pressure, and the wearing of special laboratory clothing and
gloves. Respirators should be certified by the National Institute
for Occupational Safety and Health. A minimal-level respirator
is the N-95 respirator; a purified air–powered respirator is an
option that some laboratories have found to be more com-
fortable for technicians working many hours at a biological
safety cabinet. A respirator program should be implemented
when respirator use is necessary. Personnel should be regularly
monitored by performing a tuberculin skin test at least annually
[54, 58].
TESTING AND PRIORITIZING SPECIMENS
Regardless of the many recent advances in implementing mo-
lecular techniques in the mycobacteriology laboratory, micro-
scopic examination for AFB remains an inexpensive and rapid
means for identifying highly infectious tuberculosis patients. It
allows a quantitative estimation of the number of bacilli being
excreted and therefore remains the cornerstone of infection con-
trol. Smear results should be available for the physician within
24 h of specimen collection [55] or, if an off-site laboratory is
used, within 24 h after they receive the specimen [59]. Whereas
the specificity of microscopic examination for AFB is excellent
(89%–100%), microscopic examination has 2 serious draw-
backs: it is unable to distinguish tuberculosis bacilli from non-
tuberculous mycobacteria, and it has low sensitivity [60, 61].
High-volume laboratories may use fluorescent staining to re-
duce the time for screening slides and to increase sensitivity.
Molecular tests, such as NAA assays, should be used for rapid
confirmation of suspected tuberculosis cases in patients who
have a sputum specimen positive by AFB smear [62]. Since
1999, the Mycobacterium tuberculosis direct test (MTD; Gen-
Probe) has also been approved for AFB smear–negative res-
piratory specimens. NAA tests, including PCR, transcription-
mediated amplification, ligase chain reaction, and strand
displacement amplification, may enhance diagnostic certainty,
particularly for patients for whom prompt treatment is im-
perative. However, the results of molecular methods, like other
laboratory findings, should always be interpreted in conjunc-
tion with the patients’ clinical data [63]. Pfyffer et al. [64]
showed that NAA techniques had similar sensitivity and spec-
ificity overall for respiratory and nonrespiratory specimens.
These tests can be done in as few as 3 h, allowing same-day
reporting of results. These tests should be done only in labo-
ratories that are proficient in their use. However, an NAA
method does not replace the need to perform cultures, because
culture is still required for the identification of nontuberculous
mycobacteria, as well as for susceptibility testing of a specimen
that contains M. tuberculosis complex.
Few studies have addressed the use of NAA assays for non-
respiratory specimens [64, 65]. Paradoxically, for extrapul-
monary tuberculosis (e.g., tuberculosis meningitis), a rapid and
accurate laboratory diagnosis is of prime importance because,
often, a smear has negative results and cultures yield M. tu-
berculosis only after several weeks, if at all. Tuberculosis of the
CNS remains among the most malignant of all forms of human
tuberculosis. It is responsible for high rates of death and neu-
rological disability and is often very difficult to diagnose [66,
67]. Smears of CSF samples yield positive results for !10% of
patients in some reports [68, 69]. Even though culture of CSF
is also an unreliable diagnostic technique, a positive mycobac-
terial culture remains the reference standard for diagnosis of
tuberculous meningitis [70, 71]. However, one may challenge
the dogma that culture is the reference standard and instead
stress that confirmed clinical diagnosis is the criterion against
which new microbiological assays should be assessed. After they
modified the pretreatment step for the MTD assay, Pfyffer et
al. [64] reported a sensitivity of 93.1% and specificity of 97.0%.
In another MTD study, the cutoff value was lowered from
30,000 relative lights units to 11,000, and sensitivity increased
from 33% to 83%, while specificity remained 100% [72]. Bon-
ington et al. [73] reported that the AMPLICOR test (Roche)
had a sensitivity of 60% and specificity of 100% for detecting
cases of definite and probable tuberculosis meningitis in pa-
tients treated for !10 days from whom CSF specimens had
been obtained. AMPLICOR was more sensitive than the com-
bination of AFB smear microscopy and radiometric growth
detection.
Most recently, Caws et al. [74] reported data from a national
molecular diagnostic service for tuberculosis meningitis in the
United Kingdom. Their PCR method, targeted to the genetic
element IS6110, revealed a sensitivity of 75% compared with
positive culture results and 35% compared with the final clinical
diagnosis of tuberculosis meningitis. In contrast, culture yielded
positive results in 17% of cases only when compared with clin-
ical diagnosis. Of the diagnostic tests for tuberculosis meningitis
that provide a better sensitivity than culture, NAA is currently
the most rapid, although it still is not optimal. CSF specimens
from patients suspected of having tuberculosis meningitis
should be processed immediately. Lumbar punctures should be
done with some forethought regarding the volumes of fluid
and delivery speed needed for diagnosis. At least 5 mL of CSF
should be submitted to the mycobacteriology laboratory as
quickly as possible for culture and NAA testing.
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In an international collaborative quality control study that
involved 30 laboratories, Noordhoek et al. [75] assessed the
reliability of NAA methods in detecting infection with M. tu-
berculosis complex. Each laboratory was asked to use their rou-
tine NAA technique to detect tuberculosis bacilli in a blinded
panel of 20 sputum specimens containing 0, 100, or 1000 cells
of M. bovis BCG. As reported in 1994 [76] in a preliminary
study, results were, again, disappointing, inasmuch as only 16%
of all laboratories were able to correctly identify the presence
or absence of M. bovis BCG in the 20 samples. Irrespective of
the targets and technology used, this study showed very ele-
gantly that lack of specificity was more of a problem than was
lack of sensitivity, that test reliability was not associated with
any particular method, and, worst, that many of the partici-
pating laboratories did not use adequate quality control. These
facts clearly underline the need for good laboratory practice
and reference reagents to monitor the performance of NAA
assays, including pretreatment of clinical samples.
Although the AFB smear cannot differentiate between M.
tuberculosis complex organisms and nontuberculous mycobac-
teria, a molecular-biological approach that makes use of flu-
orescence in situ hybridization appears promising. Specific pep-
tide nucleic-acid probes were used to detect M. tuberculosis
complex organisms in positive broth cultures [77, 78] or in
AFB-positive sputum smears [79]. This fluorescence in situ
hybridization assay could be an asset in the armamentarium
of peripheral laboratories that serve communities with a sub-
stantial fraction of nontuberculous mycobacteria diseases, be-
cause no amplification equipment is needed.
Before cultures for AFB can be performed, the majority of
clinical specimens must be subjected to a pretreatment involv-
ing homogenization, decontamination, and concentration. This
holds true for respiratory, gastric fluid, and urine specimens,
as well as other specimens from nonsterile body sites, primarily
to eradicate more-rapidly growing contaminants, such as nor-
mal flora bacteria and fungi, while not seriously affecting the
viability of the mycobacteria. Specimens are cultured for the
following reasons: culture is more sensitive than microscopy
(it is able to detect as few as 10 bacteria/mL [80]); growth of
the organisms is necessary for precise species identification;
drug susceptibility testing requires viable culture of the organ-
isms; and genotyping of cultured organisms can be used for
epidemiological purposes or to detect false-positive results.
The sensitivity of culture is 80%–85%, and its specificity is 98%
[81, 82].
Use of liquid culture medium and at least 1 solid medium
are recommended to increase the yield of mycobacteria [54].
For AFB smear–positive specimens, inoculation of an additional
biplate that contains both a plain and a selective Middlebrook
agar (e.g., 7H10 or selective 7H11 medium) enhances the qual-
ity of the test results. Broth-based systems have decreased the
time to detection to 1–3 weeks, compared with 3–8 weeks for
growth on solid media [81]. However, a solid medium has to
be used for those occasional strains that may not grow in liquid
media. In particular, this holds true for M. haemophilum, which
grows easily on a chocolate agar plate at 30C. The decision to
use a specific broth system depends on various factors: the
labor-saving potential, the management of radioactive waste
disposal, and the potential dangers associated with needle punc-
tures. Growth on solid media should be quantified, whereas
growth in liquid media cannot be similarly quantitated.
The genus Mycobacterium consists of almost 100 different
species, all of which appear similar on AFB staining. Many of
these can be isolated from humans, although many are found
in the environment. A specialized laboratory should be able to
provide a precise species identification of most AFB isolated
from humans. In contrast, the distinction between pathogen
and saprophyte is not always clear-cut for isolates from a given
individual. Each mycobacterial isolate, like each patient, must
be evaluated individually with respect to its potential to cause
disease [83].
Use of nucleic-acid probe kits was a quantum leap forward
in the rapid identification of M. tuberculosis complex, Myco-
bacterium avium complex, M. avium, Mycobacterium intracel-
lulare, Mycobacterium kansasii, and Mycobacterium gordonae in
culture because results are available within 2 h [54]. In rare
instances, cross-reaction has been documented when the test
is not done precisely as indicated in the package insert [84–86].
The probe technology has a sensitivity and specificity of nearly
100% [87] when at least 105 organisms are present, except for
M. kansasii (87%) [88]. Thus, these probes are not sensitive
enough to be used directly on sputum specimens, which should
be tested by means of NAA. Also, differentiation by means of
physiological, biochemical, and molecular tests should be done
to identify the species within the M. tuberculosis complex, at
least for M. bovis, M. bovis BCG, M. microti, M. canettii, and
M. africanum.
Recently reported comparative genomic studies that make
use of the complete DNA sequence of M. tuberculosis have
provided information about regions of the genome that are
deleted in most BCG derivatives and also in some other mem-
bers of the M. tuberculosis complex [89]. Parsons et al. [90]
have investigated the use of molecular amplification procedures
to determine the presence or absence of specific regions of the
genome in 88 well-characterized members of the M. tuberculosis
complex. M. bovis BCG and M. microti were each found to
have unique genotypes. Alternatively, M. africanum was found
to be the most diverse genetically (with 5 different genotypes:
3 unique, 1 shared with M. tuberculosis, and 1 shared with M.
bovis). On the basis of these results, a group of 5 assays has
been proposed to rapidly differentiate between species within
the M. tuberculosis complex [90].
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Larger laboratories may use high-performance liquid chro-
matography (HPLC) for the analysis of mycolic acids (b-
hydroxy-a-fatty acids) as a tool to identify mycobacteria from
culture [91] and from sputum [92, 93]. Ultraviolet HPLC is
not as sensitive as NAA assays done directly on sputum, but
fluorescent HPLC is being used for rapid direct testing on
sputum [93]. A distinct advantage of HPLC is the easy differ-
entiation of M. bovis BCG from M. tuberculosis and M. bovis
[94]. HPLC cannot, however, differentiate M. bovis from M.
tuberculosis.
A PCR restriction-fragment–length polymorphism proce-
dure based on the 65-kDa heat shock protein, which is capable
of rapidly identifying many species of mycobacteria that are
encountered in clinical practice, can also be used for the iden-
tification of AFB isolates that grow in liquid or solid media
[95, 96]. This testing can be done with less biomass than re-
quired by either the AccuProbe or ultraviolet HPLC tests, and
it can identify M. tuberculosis complex as well as many non-
tuberculous mycobacteria rapidly, ultimately leading to better
patient management.
A still-developing technology that appears promising for
clinical mycobacteriology laboratories involves oligonucleotide
arrays or “DNA chips”—molecular biology meets computer
technology. Gingeras et al. [97] used such an array, which has
been designed to determine the specific nucleotide-sequence
diversity in 10 species, to examine 121 mycobacterial isolates,
both by means of conventional dideoxynucleotide sequencing
of the rpoB and 16S ribosomal RNA genes and by means of
analysis of the rpoB oligonucleotide array hybridization pat-
terns. Species identification for each of the isolates was similar,
irrespective of the method used.
Drug resistance is associated with large bacterial populations,
as found, for example, in lung cavities caused by tuberculosis.
Resistance that appears during drug treatment is due to selec-
tion and multiplication of naturally occurring mutants that are
already present in the host’s population of M. tuberculosis. In-
itially, antituberculosis drugs kill the susceptible organisms,
which predominate in the population, and then the resistant
organisms multiply. Killing of susceptible organisms and sub-
sequent growth of drug-resistant mutants results in the “fall
and rise” phenomenon demonstrated in sputum samples from
patients in the late 1940s, which is described in a recent review
of drug resistance in tuberculosis [98]. In 1986, the British
Medical Research Council published data about the influence
of initial drug resistance on the response to short-course che-
motherapy for pulmonary tuberculosis [44]. They found that,
in contrast to the high success rate for short-course regimens
in patients whose infections were initially resistant to isoniazid
and streptomycin, the response of the few patients with initial
resistance to rifampin was poor. Because the recognition of
rifampin resistance is vital for the patient’s outcome, suscep-
tibility testing must to be initiated as soon as possible.
Drug susceptibility tests should be done on initial isolates
from all patients to decide on an effective antituberculosis reg-
imen [53]. Additionally, drug susceptibility studies should be
repeated if the patient continues to have culture results positive
for mycobacteria after 3 months of treatment or if the disease
reactivates. This approach has been found to be especially im-
portant during outbreaks of multiple-drug–resistant tubercu-
losis [53]. Drug-resistant tuberculosis should be suspected and
the laboratory notified if affirmative answers are given to the
following questions: Is the patient a contact of a known patient
with drug-resistant tuberculosis? Has the patient been treated
previously for tuberculosis? Is the patient having failure of tu-
berculosis treatment (i.e., are cultures still positive after 3
months)? Is the patient from a region or country with a sig-
nificant incidence of drug-resistant tuberculosis?
It is well known that the radiometric BACTEC method (BD
Biosciences) generates rapid results for the 5 first-line antitu-
berculosis drugs (rifampin, isoniazid, ethambutol, streptomy-
cin, and pyrazinamide) [99]. Because of the serious impact of
resistant strains on patient management, drug resistance should
be confirmed either by a second method or by a second lab-
oratory—especially to rule out mixed cultures of M. tuberculosis
and nontuberculous mycobacteria that will produce false re-
sistance-patterns. In the case of drug resistance, second-line
drugs may be tested by means of the proportion method [99,
100] or a radiometric protocol [101]. Susceptibility results
should be reported without delay by telephone or fax to the
health care provider, infection control, and the local tubercu-
losis control program [53].
Telenti et al. [102] demonstrated the usefulness of molecular
techniques for detecting resistance by using PCR single-
strand–conformation polymorphism analysis. Mutations in the
rpoB gene (which encodes the b subunit of RNA polymerase)
[103] were identified in all rifampin-resistant isolates and in
none of the susceptible strains—although, due to operator er-
ror, the actual sensitivity of the blind study was 96%. More
than 96% of rifampin resistance in M. tuberculosis correlates
with mutations in an 81-bp segment of the rpoB gene. Not
only does rifampin play a pivotal role in the treatment of tu-
berculosis, rifampin resistance is a surrogate marker for mul-
tiple-drug resistance in M. tuberculosis [104–106]. The now
commercially available kit-based Inno-LiPA Rifotuberculosis
assay (Innogenetics) performed equally well in identifying rpoB
mutations [102] and can, furthermore, be used for the direct
detection of M. tuberculosis complex at the same time. This
technology has recently been extended to allow direct detection
and identification of a number of nontuberculous mycobac-
teria, as well [107].
In contrast to the situation for tuberculosis bacilli, suscep-
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tibility testing of nontuberculous mycobacteria awaits stan-
dardization. Only a few general guidelines for specific suscep-
tibility testing are available, including the testing of isolates of
clinically significant and rapidly growing species (including My-
cobacterium fortuitum, Mycobacterium chelonae, and Mycobac-
terium abscessus), M. kansasii, and M. avium complex from
patients who previously were treated with macrolides [83].
Recent technical advances in the field of molecular biology,
in conjunction with a improved understanding of the molecular
genetics of mycobacteria, have provided the means to type
strains of M. tuberculosis reliably at the DNA level [108]. Ge-
notyping or DNA fingerprinting of M. tuberculosis provides
epidemiological data to assess whether a manifest tuberculosis
episode is a reactivation of disease [109], a recent transmission
of disease [110, 111], or an exogenous reinfection [112], or
whether a positive culture result was due to cross-contami-
nation in the laboratory or at bronchoscopy [113]. In addition,
genotyping is able to give us an idea about how M. tuberculosis
is transmitted in a community [114–116]. Most often, restric-
tion-fragment–length polymorphism patterns are generated by
targeting the genetic element IS6110, which is one of the nu-
merous mobile genetic elements in mycobacteria. IS6110 is a
naturally occurring transposable genetic element, which ap-
pears to be detectable in species of the M. tuberculosis complex
only. Each strain of M. tuberculosis contains a different number
of identical copies of this transposable element, except some
Asian strains that are devoid of the IS6110 element [117–119].
The number of copies of IS6110 elements and the molecular
size of the restriction fragments obtained after PvuII digestion
vary in such a way that 2 unrelated strains do not produce
identical patterns when hybridized with a labeled probe for
IS6110, but produce unique genetic fingerprints.
A standardized protocol is available for strain identification
by DNA fingerprinting [120]. Patterns and dendrograms, which
illustrate the degree of relatedness among the isolates, can easily
be assessed by computer analysis. Spoligotyping [121], as well
as other methods, provide typing that is even more rapid, be-
cause as they use PCR to amplify the genetic material being
typed. The CDC, through its National Tuberculosis Genotyping
and Surveillance Network, offers rapid and accurate strain typ-
ing nationwide and at no cost. For submission of M. tuberculosis
isolates to 1 of the 7 designated sites, the local state public
health laboratory should be contacted.
LABORATORY SERVICES: WHAT SURVEYS
TOLD US
In December 1991, the CDC, in collaboration with the Asso-
ciation of Public Health Laboratories, surveyed state and ter-
ritorial mycobacteriology laboratories [122]. Twenty-seven per-
cent of the laboratories (which process 31% of total specimens)
used the radiometric growth detection system, in addition to
a solid medium. Seventy-one percent of the laboratories (which
process 81% of total specimens) used nucleic-acid probes or
HPLC for identification of mycobacteria. Finally, 20% of the
laboratories (which process 80% of total specimens) were using
the radiometric method for susceptibility testing of M. tuber-
culosis. The time required for reporting test results was variable.
To identify M. tuberculosis in clinical specimens took an average
of 31 days (range, 5–80 days) from the time of specimen receipt,
and drug susceptibility results were available in 42 days (range,
18–76 days). Laboratories that used radiometric growth detec-
tion, nucleic-acid probes, or HPLC for identification and ra-
diometric susceptibility testing reported susceptibility testing
results in a mean of 31 days (SD, 11 days). No information
was provided about the specimen load at the state and territorial
public health laboratories compared with the load for the entire
United States.
Because mycobacteriology laboratories play an important
role in the control of tuberculosis, especially for drug-resistant
cases, a questionnaire was sent in 1994 to 188 laboratories that
hold a New York State permit in mycobacteriology to assess
real turnaround times under field conditions for all respiratory
specimens that were initially smear-positive [123]. There were
records for 2620 patients and 3013 respiratory specimens that
were considered to be initially smear-positive for mycobacteria.
Culture results for these specimens were as follows: M. tuber-
culosis complex, 1554 specimens (52%); nontuberculous my-
cobacteria, 1160 specimens (39%); and negative culture result
or contaminated, 334 specimens (11%). The time elapsed be-
tween the date that smear-positive sputum specimens contain-
ing M. tuberculosis complex were collected and the date that
susceptibility testing results for rifampin were reported to the
physician was 8–9 weeks for 80% of isolates. In contrast, the
New York State Department of Health’s Fast Track for Tuber-
culosis Testing program provided susceptibility testing results
to clinicians in only 4 weeks for 80% of isolates.
These surveys were triggered by the resurgence of tubercu-
losis, the recognition of the synergism with HIV infection, and
the need for rapid results from the mycobacteriology laboratory.
They provided baseline data that revealed that newer assays
were not widely in use in the United States. This can be con-
trasted to the list of the range of services offered by the Florida
Department of Health’s FAST TRACK program (table 2).
ASSESSING A LABORATORY’S PERFORMANCE
External quality control schemes. The College of American
Pathologists, the largest provider of proficiency testing in this
country, has offered a program in mycobacteriology since 1969
[124]. In recent years, the CDC’s Public Health Practice Pro-
gram Office has offered 2 different performance evaluation pro-
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grams for the testing of M. tuberculosis complex: 1 for drug
susceptibility testing, since 1994, and 1 for NAA testing, since
1997. As of September 2000, 130 US institutions were enrolled
in the drug susceptibility testing program (which requires BSL-
3 practices), and 100 were enrolled in the NAA testing program
(which requires BSL-2 practices; personal communication, J.C.
Ridderhof). The programs provide aggregate reports of testing
results that are useful for self-assessment of performance. This
information may allow individual laboratories to identify prob-
lems in laboratory testing protocols and/or testing algorithms.
There are no enrollment fees for participation. More informa-
tion is available at the CDC Web site, at http://www.phppo.cdc
.gov/mpep.
Current Clinical Laboratory Improvement Amendments of
1988 regulations require ∼40% of all federally registered test
facilities to participate in a proficiency testing program ap-
proved by the Centers for Medicare and Medicaid Systems. The
maintenance of clinical laboratory operating licenses at state
and federal levels is chiefly dependent on successful perform-
ance on proficiency tests. However, whereas assessment for per-
formance of compatibility testing and ABO blood group typing
require a score of 100% to pass, and for performance of Pa-
panicolaou smears, a score of 90%, the passing score for all
other categories, including microbiology, is only 80% [125].
This sharply contrasts with the quest for fewer errors in the
provision of health care [126–128].
Laboratory capabilities. How can the health care provider
assess the performance of a laboratory and distinguish a state-
of-the-art laboratory from a conventional one that has built-
in testing delays? The following recommendations, given in the
form of questions, may serve as a guide for the clinician who
is attempting to assess laboratory methods; they cover standards
of laboratory practice, turnaround times, and quality assurance
[129].
1. Does the laboratory perform or have access to the newest
technology, such as NAA tests, for testing of specimens from
patients with AFB smear–positive sputum samples and for pa-
tients with clinical and radiological signs of tuberculosis in spite
of AFB smear–negative sputum samples?
2. Does the laboratory inoculate specimens into at least 1
liquid and 1 solid medium for detection of growth of
mycobacteria?
3. Does the laboratory use rapid identification tests for M.
tuberculosis complex, such as nucleic-acid probe kits or HPLC?
4. Does the laboratory confirm the identification of drug-
resistant strains of M. tuberculosis either by a second method
or by a second laboratory?
5. Is the result of the AFB sputum smear available within
24 h of specimen collection?
In addition, the laboratory should be asked about its turn-
around times. Rapid reporting of results is paramount for cor-
rect patient management and essential for prompt evaluation
of the contacts of the index case. Any case of tuberculosis must
be reported to the public health authorities. The laboratory
must make an effort to report results rapidly, including trans-
mission of results by telephone, fax, and electronic information
system. Turnaround time for susceptibility testing results is an
excellent marker for overall laboratory performance. For ex-
ample, for specimens that are initially smear-positive and cul-
ture-positive, the New York State Department of Health re-
quires that, for M. tuberculosis, the laboratories monitor the
time elapsed between the date the specimen is taken and the
date the result of testing for susceptibility to rifampin is re-
ported to the health care provider. In addition, the clinician
may ask the tuberculosis laboratory about participation (and
scores) in external quality control (proficiency testing) pro-
grams. If any of the answers are “no” or not satisfying (e.g.,
passing scores of only 80%–90%), the issue should be discussed
with the laboratory director or another expert in the field.
Alternatively, another laboratory may be chosen to ensure high
standards of microbiological testing [9].
GOALS
In January 2000, the US Department of Health and Human
Services published “Healthy People 2010—Understanding and
Improving Health” [130], which lists the wide range of public
health opportunities that exist in the first decade of the 21st
century. The report discusses 467 objectives in 28 focus areas,
and includes the following 4 tuberculosis targets: to reduce the
incidence of tuberculosis, to increase the proportion of all tu-
berculosis patients who complete curative therapy within 12
months, to increase the proportion of contacts and other high-
risk persons with latent tuberculosis who complete a course of
treatment, and to reduce the average time it takes for a labo-
ratory to confirm and report tuberculosis cases (see table 3).
The technology is already at hand: it is only a matter of
organizing the most efficient laboratory service to meet the
fourth target by 2010. With these targets in mind, care of the
following patients should be expedited: patients with newly
diagnosed AFB smear–positive sputum samples; patients with
clinical and radiological signs of tuberculosis despite AFB
smear–negative sputum samples; and patients who are suspects
of having drug-resistant tuberculosis [131].
The Institute of Medicine report “Ending Neglect: The Elim-
ination of Tuberculosis in the United States” [132] reviews the
lessons learned from the neglect of tuberculosis between the
late 1960s and the earlier 1990s and reaffirms a commitment
to the goal of eliminating tuberculosis in the United States,
which is defined as a case rate of !1 case per million population
per year. The report states, “to meet this goal, aggressive and
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Table 3. Goals of the “Healthy People 2010” initiative for tuberculosis [130].
Goal number and description Target Baseline value
14-11: Reduce tuberculosis 1 new case per 100,000
population per year
6.8 new cases per 100,000
population in 1998
14-12: Increase proportion of all tuberculo-
sis patients who complete curative ther-
apy within 12 months
90% of patients 74% of patients in 1996
14-13: Increase proportion of contacts and
other high-risk persons with latent tuber-
culosis infection who complete course
of treatment
85% of persons 62.2% of persons in 1997
14-14: Reduce average time for laboratory
to confirm and report tuberculosis cases
2 days for 75% of
cases
21 days for 75% of cases
in 1996
decisive actions beyond what is now in effect will be required,”
and offers a quote from Goethe: “Knowing is not enough; we
must apply; / Willing is not enough; we must do” [132]
We—health care providers, laboratorians, and public health
practitioners—must strive for a new type of leadership that
merges all of the different players involved into a synergistic
network, making the whole of the virtual organization more
effective than the sum of its parts.
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